Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations
Christina S. Thornton(Alberta Health Services), John J. LiPuma, Natalie E. West(Johns Hopkins University), Patrick A. Flume(Medical University of South Carolina), William LeBar(University of Michigan), Lisa A. Carmody(University of Michigan), Scott McClellan(University of Michigan), Donald R. VanDevanter(Case Western Reserve University), Lindsay J. Caverly(University of Michigan), Christopher H. Goss(Seattle Children's Hospital), Linda M. Kalikin(University of Michigan), Sonya L. Heltshe, Don B. Sanders(Indiana University Bloomington)
Cited by 20
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
|American Journal of Respiratory and Critical Care Medicine|2017|393
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study
|American Journal of Respiratory and Critical Care Medicine|2018|343
Pulmonary complications after esophagectomy
|The Annals of Thoracic Surgery|2002|289
CFTR modulator theratyping: Current status, gaps and future directions
|Journal of Cystic Fibrosis|2018|288